

In the claims:

Please cancel claims 2,49 without prejudice, and add new claims 50-59 as follows:

- Sub C1
50. A method for inducing *ex vivo* proliferation of a population of T cells, comprising:  
contacting a population of T cells *ex vivo* with a solid phase surface having covalently attached thereto:  
(a) a first agent which provides a primary activation signal to the T cells, thereby activating the T cells; and  
(b) a second agent which stimulates an accessory molecule on the surface of the T cells, thereby stimulating the activated T cells,  
the first and second agents thereby inducing the population of T cells to proliferate.
51. The method of claim 50, wherein the first agent stimulates a TCR/CD3 complex-associated signal in the T cells.
52. The method of claim 50, wherein the first agent is an anti-CD3 antibody.
53. The method of claim 52, wherein the anti-CD3 antibody is an anti-human CD3 monoclonal antibody.
54. The method of claim 50, wherein the accessory molecule on the T cell is CD28.
55. The method of claim 54, wherein the second agent is an anti-CD28 antibody.
56. The method of claim 54, wherein the second agent is a stimulatory form of a natural ligand of CD28.
57. The method of claim 50, further comprising:  
monitoring proliferation of the T cells; and  
reactivating and re-stimulating the T cells with the first and second agents when the rate of T cell proliferation has decreased to induce further proliferation of the T cells.
58. The method of claim 57, wherein the step of monitoring proliferation of the T cells is by examining cells size or determining the level of expression of a cell surface molecule, and the step of reactivating and re-stimulating is initiated when T cell size has decreased or when the level of the cell surface molecule has decreased.
- 6680/01/000560